Trailing-twelve-month (TTM) revenue is $1.52 Billion with a year-over-year growth of +17.12%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $363,893,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q2 FY2026Period ended 2025-12-31 | $373,910,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-04 |
| Q3 FY2026Period ended 2026-03-31 | $383,543,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q4 FY2026Period ended 2026-06-30 | $396,747,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-26 |
| TTM revenue | $1,518,093,000 |
Current P/S: $1,484,046,548 market capitalization ÷ $1,518,093,000 TTM revenue = 0.98x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:25:09.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $396.75M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:27:54.229Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Animal Health | $73M | $607M | N/A | N/A | N/A | N/A |
| Mineral Nutrition | $221M | $260M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Asia Pacific | $58M | $67M | $61M | $63M | $97M | $112M |
| EMEA | N/A | $122M | $118M | $122M |
$1.52B
$1.52 Billion
+17.12%
vs. $1.30B a year ago (TTM)
+12.75%
5 Year compound annual growth rate
1 Year
+17.12%
3 Year
+15.79%
5 Year
+12.75%
10 Year
+7.28%
15 Year
+6.28%
20 Year
+6.92%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $1.52B | +$221.88M | +17.12% |
| 2025 | $1.30B | +$278.54M | +27.37% |
| 2024 | $1.02B | +$39.79M | +4.07% |
| 2023 | $977.89M | +$35.63M | +3.78% |
| 2022 | $942.26M | +$108.91M | +13.07% |
| 2021 |
TTM Growth
+17.12%
3-Year CAGR
+15.79%
5-Year CAGR
+12.75%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:27:54.229Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| Performance Products | $67M | $76M | N/A | N/A | N/A | N/A |
|---|
| Vaccines | N/A | N/A | $100M | $121M | $137M | $156M |
|---|
| $160M |
| $188M |
| Europe Middle East And Africa | $114M | N/A | N/A | N/A | N/A | N/A |
|---|
| Latin America and Canada | N/A | $191M | $220M | $248M | $299M | $341M |
|---|
| Latin America And Canada | $166M | N/A | N/A | N/A | N/A | N/A |
|---|
| U | $495M | N/A | N/A | N/A | N/A | N/A |
|---|
| UNITED STATES | N/A | $562M | $579M | $585M | $740M | $877M |
|---|
| $833.35M |
| +$33.00M |
| +4.12% |
| 2020 | $800.35M | ($27.65M) | (3.34%) |
| 2019 | $828.00M | +$8.00M | +0.98% |
| 2018 | $820.00M | +$55.70M | +7.29% |
| 2017 | $764.30M | +$12.80M | +1.70% |
